NCT06018194

Brief Summary

The goal of this study is to evaluate the diagnostic accuracy of a novel plaque-based coronary CT angiography (CCTA) fractional flow reserve (FFRct) software device for the estimation of invasive fractional flow reserve (FFR). Researchers will compare the Elucid plaque-based FFRct analysis to invasively measured FFR in patients who have previously undergone CCTA and invasively assessed FFR.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
350

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2023

Shorter than P25 for all trials

Geographic Reach
1 country

9 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 23, 2023

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 30, 2023

Completed
2 days until next milestone

Study Start

First participant enrolled

September 1, 2023

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2024

Completed
Last Updated

February 20, 2024

Status Verified

February 1, 2024

Enrollment Period

11 months

First QC Date

August 23, 2023

Last Update Submit

February 15, 2024

Conditions

Keywords

coronary computed tomographic angiographycoronary CTAcardiac CTfractional flow reserveplaque

Outcome Measures

Primary Outcomes (2)

  • Sensitivity of FFRct versus invasive FFR for detecting invasive FFR ≤ 0.80

    Per-vessel

    1 day

  • Specificity of FFRct versus invasive FFR for detecting invasive FFR ≤ 0.80

    Per-vessel

    1 day

Secondary Outcomes (10)

  • Sensitivity of FFRct for detecting invasive FFR ≤ 0.80

    1 day

  • Specificity of FFRct for detecting invasive FFR ≤ 0.80

    1 day

  • Area under the receiver-operating characteristic curve (AUC) of FFRct for detecting invasive FFR ≤ 0.80

    1 day

  • Area under the receiver-operating characteristic curve (AUC) of FFRct for detecting invasive FFR ≤ 0.80

    1 day

  • Accuracy of FFRct for detecting invasive FFR ≤ 0.80

    1 day

  • +5 more secondary outcomes

Study Arms (2)

Low FFR

Invasive FFR \<= 0.80

Device: ElucidVivo

High FFR

Invasive FFR \> 0.80

Device: ElucidVivo

Interventions

Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)

High FFRLow FFR

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults \>=18 years with at least one 30-90% stenosis on CCTA (\>64- detector row) performed within 60 days of undergoing invasive FFR.

You may qualify if:

  • \- Adults \>=18 years with at least one 30-90% stenosis on CCTA (\>64- detector row) performed within 60 days of undergoing invasive FFR.

You may not qualify if:

  • History of coronary revascularization with coronary artery bypass graft (CABG) surgery and/or percutaneous coronary intervention (PCI) (stent or balloon angioplasty) prior to CCTA and invasive FFR.
  • History of myocardial infarction prior to CCTA and invasive FFR.
  • Known complex congenital heart disease.
  • Existing pacemaker or internal defibrillator lead implantation(s).
  • Existing prosthetic heart valve.
  • Absence of CCTA Digital Imaging and Communications in Medicine (DICOM) data for analysis.
  • Absence of invasive coronary angiography imaging or adequate description defining the position of the invasive FFR wire location.
  • Poor CCTA image quality that does not meet Elucid image processing requirements for plaque and FFRct.
  • Absence of study date for CCTA or invasive FFR.
  • Interval clinical myocardial infarction, diagnosis of decompensated heart failure, stroke, or coronary revascularization procedure between CCTA and invasive FFR.
  • Non-diagnostic CCTA or invasive FFR. Studies where the results of the study were deemed non-diagnostic for clinical decision-making will be excluded.
  • CCTA or invasive FFR studies performed prior to 1 January 2016.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Cardiovascular Medical Group of Southern California

Beverly Hills, California, 90210, United States

NOT YET RECRUITING

Piedmont Healthcare

Atlanta, Georgia, 30309, United States

NOT YET RECRUITING

Parkview Health

Fort Wayne, Indiana, 46845, United States

NOT YET RECRUITING

Midwest Heart and Vascular Specialists

Overland Park, Kansas, 66211, United States

RECRUITING

Valley Health System

Ridgewood, New Jersey, 07450, United States

NOT YET RECRUITING

Cleveland Clinic

Cleveland, Ohio, 44195, United States

NOT YET RECRUITING

Centennial Heart

Nashville, Tennessee, 37203, United States

NOT YET RECRUITING

Ascension Medical Group

Nashville, Tennessee, 37205, United States

NOT YET RECRUITING

University of Virginia

Charlottesville, Virginia, 22908, United States

RECRUITING

Related Publications (9)

  • Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS Jr, Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM, Zwischenberger BA. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 Jan 18;145(3):e4-e17. doi: 10.1161/CIR.0000000000001039. Epub 2021 Dec 9.

    PMID: 34882436BACKGROUND
  • Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O'Connor RE, Ross MA, Shaw LJ. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Nov 30;144(22):e368-e454. doi: 10.1161/CIR.0000000000001029. Epub 2021 Oct 28.

    PMID: 34709879BACKGROUND
  • Tesche C, De Cecco CN, Caruso D, Baumann S, Renker M, Mangold S, Dyer KT, Varga-Szemes A, Baquet M, Jochheim D, Ebersberger U, Bayer RR 2nd, Hoffmann E, Steinberg DH, Schoepf UJ. Coronary CT angiography derived morphological and functional quantitative plaque markers correlated with invasive fractional flow reserve for detecting hemodynamically significant stenosis. J Cardiovasc Comput Tomogr. 2016 May-Jun;10(3):199-206. doi: 10.1016/j.jcct.2016.03.002. Epub 2016 Mar 10.

    PMID: 26993434BACKGROUND
  • Ahmadi A, Stone GW, Leipsic J, Serruys PW, Shaw L, Hecht H, Wong G, Norgaard BL, O'Gara PT, Chandrashekhar Y, Narula J. Association of Coronary Stenosis and Plaque Morphology With Fractional Flow Reserve and Outcomes. JAMA Cardiol. 2016 Jun 1;1(3):350-7. doi: 10.1001/jamacardio.2016.0263.

    PMID: 27438119BACKGROUND
  • Diaz-Zamudio M, Dey D, Schuhbaeck A, Nakazato R, Gransar H, Slomka PJ, Narula J, Berman DS, Achenbach S, Min JK, Doh JH, Koo BK. Automated Quantitative Plaque Burden from Coronary CT Angiography Noninvasively Predicts Hemodynamic Significance by using Fractional Flow Reserve in Intermediate Coronary Lesions. Radiology. 2015 Aug;276(2):408-15. doi: 10.1148/radiol.2015141648. Epub 2015 Apr 17.

    PMID: 25897475BACKGROUND
  • Varga-Szemes A, Schoepf UJ, Maurovich-Horvat P, Wang R, Xu L, Dargis DM, Emrich T, Buckler AJ. Coronary plaque assessment of Vasodilative capacity by CT angiography effectively estimates fractional flow reserve. Int J Cardiol. 2021 May 15;331:307-315. doi: 10.1016/j.ijcard.2021.01.040. Epub 2021 Jan 30.

    PMID: 33529657BACKGROUND
  • Stuijfzand WJ, van Rosendael AR, Lin FY, Chang HJ, van den Hoogen IJ, Gianni U, Choi JH, Doh JH, Her AY, Koo BK, Nam CW, Park HB, Shin SH, Cole J, Gimelli A, Khan MA, Lu B, Gao Y, Nabi F, Nakazato R, Schoepf UJ, Driessen RS, Bom MJ, Thompson R, Jang JJ, Ridner M, Rowan C, Avelar E, Genereux P, Knaapen P, de Waard GA, Pontone G, Andreini D, Al-Mallah MH, Lu Y, Berman DS, Narula J, Min JK, Bax JJ, Shaw LJ; CREDENCE Investigators. Stress Myocardial Perfusion Imaging vs Coronary Computed Tomographic Angiography for Diagnosis of Invasive Vessel-Specific Coronary Physiology: Predictive Modeling Results From the Computed Tomographic Evaluation of Atherosclerotic Determinants of Myocardial Ischemia (CREDENCE) Trial. JAMA Cardiol. 2020 Dec 1;5(12):1338-1348. doi: 10.1001/jamacardio.2020.3409.

    PMID: 32822476BACKGROUND
  • Lin A, van Diemen PA, Motwani M, McElhinney P, Otaki Y, Han D, Kwan A, Tzolos E, Klein E, Kuronuma K, Grodecki K, Shou B, Rios R, Manral N, Cadet S, Danad I, Driessen RS, Berman DS, Norgaard BL, Slomka PJ, Knaapen P, Dey D. Machine Learning From Quantitative Coronary Computed Tomography Angiography Predicts Fractional Flow Reserve-Defined Ischemia and Impaired Myocardial Blood Flow. Circ Cardiovasc Imaging. 2022 Oct;15(10):e014369. doi: 10.1161/CIRCIMAGING.122.014369. Epub 2022 Oct 13.

    PMID: 36252116BACKGROUND
  • Buckler AJ, Sakamoto A, Pierre SS, Virmani R, Budoff MJ. Virtual pathology: Reaching higher standards for noninvasive CTA tissue characterization capability by using histology as a truth standard. Eur J Radiol. 2023 Feb;159:110686. doi: 10.1016/j.ejrad.2022.110686. Epub 2022 Dec 31.

    PMID: 36603478BACKGROUND

MeSH Terms

Conditions

Coronary Artery DiseasePlaque, Amyloid

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • Ziad Ali, MD

    Catholic Health - St. Francis Hospital

    PRINCIPAL INVESTIGATOR
  • Todd C Villines, MD

    Elucid Bioimaging Inc.

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Todd C Villines, MD

CONTACT

John Aluru, MBBS

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 23, 2023

First Posted

August 30, 2023

Study Start

September 1, 2023

Primary Completion

July 31, 2024

Study Completion

July 31, 2024

Last Updated

February 20, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share

Locations